Squarepoint
PFE icon

Squarepoint’s Pfizer PFE Stock Holding History

Squarepoint’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.5M Sell
766,200
-1,352,700
-64% -$36M 0.03% 671
2025
Q4 		$52.8M Buy
2,118,900
+483,200
+30% +$12.2M 0.06% 389
2025
Q3 		$41.7M Buy
1,635,700
+817,400
+100% +$20.2M 0.04% 465
2025
Q2 		$19.8M Sell
818,300
-543,200
-40% -$12.7M 0.02% 768
2025
Q1 		$34.5M Buy
1,361,500
+570,000
+72% +$14.9M 0.04% 460
2024
Q4 		$21M Buy
791,500
+168,300
+27% +$4.57M 0.02% 747
2024
Q3 		$18M Sell
623,200
-44,600
-7% -$1.3M 0.03% 638
2024
Q2 		$18.7M Sell
667,800
-1,366,000
-67% -$37.6M 0.03% 616
2024
Q1 		$56.4M Buy
2,033,800
+704,700
+53% +$19.6M 0.1% 220
2023
Q4 		$38.3M Buy
1,329,100
+71,200
+6% +$2.15M 0.07% 304
2023
Q3 		$41.7M Buy
1,257,900
+451,500
+56% +$16M 0.1% 209
2023
Q2 		$29.6M Buy
806,400
+374,700
+87% +$14.6M 0.09% 233
2023
Q1 		$17.6M Sell
431,700
-19,800
-4% -$855K 0.07% 310
2022
Q4 		$23.1M Sell
451,500
-273,600
-38% -$13.1M 0.09% 217
2022
Q3 		$31.7M Buy
725,100
+163,300
+29% +$7.94M 0.16% 125
2022
Q2 		$29.5M Buy
561,800
+136,600
+32% +$6.96M 0.16% 132
2022
Q1 		$22M Buy
425,200
+199,200
+88% +$10.3M 0.09% 214
2021
Q4 		$13.3M Sell
226,000
-27,900
-11% -$1.38M 0.04% 427
2021
Q3 		$10.9M Sell
253,900
-11,800
-4% -$523K 0.03% 470
2021
Q2 		$10.4M Buy
265,700
+226,100
+571% +$8.79M 0.04% 448
2021
Q1 		$1.44M Buy
39,600
+34,000
+607% +$1.21M 0.01% 1269
2020
Q4 		$206K Sell
5,600
-3,148
-36% -$115K ﹤0.01% 2490
2020
Q3 		$305K Hold
8,748
– – ﹤0.01% 1787
2020
Q2 		$271K Buy
+8,748
New +$297K ﹤0.01% 1666
2020
Q1 		– Sell
-12,121
Closed -$451K – 2356
2019
Q4 		$451K Sell
12,121
-6,956
-36% -$248K ﹤0.01% 1827
2019
Q3 		$650K Buy
19,077
+4,953
+35% +$180K 0.01% 1482
2019
Q2 		$580K Buy
14,124
+633
+5% +$25.1K 0.01% 1578
2019
Q1 		$544K Buy
+13,491
New +$540K 0.01% 1447

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Squarepoint's PFE Position: Q1 2026 in Review

Squarepoint reduced its Pfizer (PFE) stake by 44% in Q1 2026, selling an estimated $113M and leaving 5,433,651 shares worth $153M. The position accounts for 0.18% of the portfolio, ranked #86.

Squarepoint first reported a position in PFE in Q1 2015 and has held it in 41 quarters since. The position peaked at $262M in Q3 2025. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Squarepoint held 5,433,651 shares of Pfizer worth $153M as of Q1 2026.
  • Squarepoint sold 4,249,615 Pfizer shares in Q1 2026, an estimated $113M.
  • Pfizer made up 0.18% of Squarepoint's portfolio in Q1 2026, its #86 holding.
  • Squarepoint first reported a position in Pfizer in Q1 2015 and has held it in 41 quarters since.
  • Squarepoint's Pfizer position peaked at $262M in Q3 2025.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.